However, we did not expect that our groups would be segregated purely according to hormone receptor status, since tamoxifen treatment may be waived for in situ breast cancer if treated with a double mastectomy or if women express the desire in becoming pregnant. The gene discussed is NR4A1; the disease is breast carcinoma in situ.